Navigation Links
DecisionView Board of Directors Appoints James P. Scullion as CEO and President
Date:3/31/2009

High Tech Industry Veteran Will Focus on Broader Product Distribution, Revenue Growth and Profitability

SAN FRANCISCO, March 31 /PRNewswire/ -- DecisionView, Inc., the leading provider of Clinical Optimization Solutions for the Life Sciences industry, today announced that its Board of Directors has appointed James P. Scullion to the role of Chairman, President and CEO of DecisionView, effective immediately. Most recently, he held the role of Chairman for DecisionView. Scullion succeeds Steve Andrade as the Company's President and Chief Executive Officer.

"I'm very pleased that Jim has agreed to join DecisionView as its new CEO," said Chris Hollenbeck, a DecisionView Board Member. "We believe the market for clinical optimization solutions is poised for significant growth. Jim has over two decades of experience leading high tech companies, and his expertise will greatly benefit DecisionView as the company looks to extend its leadership position as a comprehensive provider of business performance optimization applications."

Mr. Scullion brings more than 20 years of experience as a "C" level executive in the high technology industry to his new position. Most recently, he served as Chairman and CEO of Tumbleweed Communications from January 2006 to September 2008. Under Mr. Scullion's leadership, Tumbleweed was successfully transformed from an email security centric company to a leading provider of secure content delivery solutions to Global 1000 and midmarket enterprises doubling its customer base from 1,700 to 3,500 customers. Tumbleweed was acquired by Sopra Group in September 2008. From January 2004 to January 2006, he was CEO of ComnetiX, Inc., a leading provider of criminal intelligence systems. During Mr. Scullion's tenure at ComnetiX, revenues grew threefold and he led the company's successful IPO on the Toronto Stock Exchange. From 1990 to 2002, he held senior management positions including President and COO with Identix Incorporated, a publicly traded biometric technology company. While at Identix, Scullion led the company's growth in annual revenues from $1 million to more than $80 million.

"DecisionView is the technology leader in the clinical recruitment optimization market," said Scullion. "I am excited to be joining a company that is well positioned to capitalize on a fast growing, high demand market. I believe my leadership and operational experience will further strengthen the already outstanding DecisionView team, and will help accelerate our company's growth as we expand and enrich our optimization solutions for the Life Sciences industry."

Steve Andrade will be leaving the company to pursue other interests and will also be stepping down from his position as a member of the DecisionView board of directors.

About DecisionView, Inc.

DecisionView develops innovative software solutions that optimize the clinical performance of life sciences organizations around the world. By uniquely converging predictive analytics, simulation, visualization and data aggregation capabilities into functionally rich and easy to use applications, the company's solutions deliver proven business value in faster cycle times, reducing clinical costs and improving clinical productivity. To learn more, visit www.decisionview.com.


'/>"/>
SOURCE DecisionView, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DecisionView Unveils the Next Generation of Clinical Trial Software: StudyOptimizer 4.0
2. Andrew Dallas, President of Full Spectrum Software Appointed to Medical Device and Diagnostic Industry Magazine Editorial Advisory Board
3. Nutrition 21s President and CEO, Elected to the Consumer Healthcare Products Association Board
4. Ingenious Med Expands Leadership and Adds Members to Board of Directors
5. AORN and Mercy Ships Collaborate to Increase Patient Care Aboard Hospital Ships
6. Loop Joins Board of Management Health Solutions, Inc.
7. Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
8. TrinityCare Appoints Kirk B. Shulke, M.D. to Board of Directors
9. RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group
10. TrinityCare Appoints Decorated Christian Artist Al Denson to Board of Directors
11. Former Merck Executive Joins Board of Clinical Information Network, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
Breaking Medicine Technology: